Haematology News and Research

RSS

Elsevier launches open access journal, Pathogenesis

Elsevier, world-leading provider of scientific, technical and medical information products and services, announces the launch of open access journal, Pathogenesis.

29 Jan 2014

Scientists develop novel treatment for Hairy Cell Leukaemia using drug administered to combat skin cancer

A team of scientists from the University of Leicester has demonstrated a novel treatment for Hairy Cell Leukaemia (HCL), a rare type of blood cancer, using a drug administered to combat skin cancer.

16 Jan 2014

NICE issues Final Appraisal Determination for PIXUVRI (pixantrone) drug

Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported that the National Institute for Health and Care Excellence (NICE), the independent body responsible for driving improvement and excellence in the health and social care system in the United Kingdom (UK), has issued its Final Appraisal Determination (FAD) for PIXUVRI® (pixantrone).

6 Jan 2014

Studies confirm superiority of Tasigna to Glivec at achieving molecular response in Ph+ CML patients

Findings from three large, randomized Phase III studies demonstrate the superiority of Tasigna (nilotinib) compared to Glivec (imatinib) at achieving deeper molecular responses across various Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) patient populations, including newly diagnosed patients, patients with residual disease who switched to Tasigna after long-term treatment with Glivec, and patients who failed to respond to frontline Glivec (as defined by 2013 European LeukemiaNet [ELN] guidelines).

9 Dec 2013

Patrys to present data from PAT-SM6 Phase I/IIa trial in multiple myeloma at ASH conference

Patrys Limited (ASX: PAB), a clinical stage biotechnology company has announced that updated results from its PAT-SM6 Phase I/IIa clinical trial in multiple myeloma will be presented at the 55th American Society of Hematology Annual Meeting in New Orleans, LA on 7- 10 December 2013.

29 Nov 2013

Data from Patrys' PAT-SM6 Phase I/IIa trial in multiple myeloma to be presented at ASH Annual Meeting

Patrys Limited, a clinical stage biotechnology company has announced that updated results from its PAT-SM6 Phase I/IIa clinical trial in multiple myeloma will be presented at the 55th American Society of Hematology Annual Meeting in New Orleans, LA on 7- 10 December 2013.

29 Nov 2013

Study uncovers new genetic pathways that could revolutionise acute dendritic leukaemia treatment

Acute dendritic leukaemia is a rare type of leukaemia, but one with the worst prognosis-the average patient survival rate is just 12-14 months-that is difficult to treat. Juan Cruz Cigudosa's team, from the Spanish National Cancer Research Centre's Molecular Cytogenetics Group, has for the first time sequenced the exome -the coding, or protein-generating, regions of the genome- of dendritic cell leukaemia.

24 Oct 2013

Vitamin D Total assay for use on Access 2 and UniCel DxI immunoassay systems receives CE Mark

Beckman Coulter, Inc. announces the CE Mark approval of Access 25 (OH) Vitamin D Total assay for use on the Access 2 and UniCel DxI series of immunoassay systems. Offering enhanced performance, the new assay is an important addition to the company’s bone metabolism assay menu.

23 Oct 2013

ESMO recognises oncologists with prestigious awards

The European Society for Medical Oncology, the leading pan-European organisation representing medical oncology professionals, announced today the recipients of the annual society's prestigious awards, recognising excellence in oncology.

5 Sep 2013

Alzheimer’s drug trial: an interview with Geoffrey Kempler, Chairman & CEO Prana Biotechnology

Approval for the IMAGINE trial was granted by the Austin Health Research Ethics Committee in November 2011, with the first patients dosed in March the following year. However, well before the trial was approved, PBT2 had already shown promise in significantly changing Abeta levels in spinal fluid while improving cognition in a previous 12-week trial conducted in 2006.

28 Aug 2013

ARIAD Pharmaceuticals' Iclusig gets EC marketing authorization for CML and Ph+ ALL treatment

ARIAD Pharmaceuticals, Inc. today announced that the European Commission has granted a marketing authorization for Iclusig (ponatinib) as an orphan medicinal product for two indications.

2 Jul 2013

Ibrutinib monotherapy shows efficacy in patients with MCL or DLBCL

Pharmacyclics, Inc. today announced the results of two separate Phase 2 studies suggesting that ibrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, showed efficacy when used as a monotherapy in patients with relapsed/refractory mantle cell lymphoma or diffuse large B-cell lymphoma.

17 Jun 2013

Vijay Tiwari from IMB receives Bruno Speck Award from Swiss Foundation of Haematological Research

Dr Vijay Tiwari, a Group Leader at the Institute of Molecular Biology (IMB) in Mainz, has been awarded the Bruno Speck Award by the Swiss Foundation of Haematological Research. The award recognises outstanding work by young scientists in the fields of haematology and stem cell research.

15 May 2013

New generation of innovative medical devices to be created by Curie-Cancer and Vygon partnership

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities and Vygon, a French family-run business that develops, produces and markets medical devices, including catheters and implantable ports for administering chemotherapy treatments, today announce their partnership to develop a new generation of innovative medical devices; mainly for use in chemotherapy. The partnership aims to introduce them to European, the US and Asian markets.

16 Apr 2013

Results from Merck’s Vorinostat phase 1 trial on lymphoma

Patients whose aggressive lymphomas have relapsed or failed to respond to the current front-line chemotherapy regimen now have an effective second line of attack against their disease.

5 Feb 2013

Enlarged lymph nodes may warn of cancer

Enlarged lymph nodes are a marker for both occult cancer and a long-term risk for malignancy, confirms research published in the British Journal of Haematology.

19 Dec 2012

Scientists discover FAIM molecule as potential biomarker for bone marrow cancer

Singapore scientists have identified FAIM, a molecule that typically prevents cell death, as a potential biomarker to identify an incurable form of cancer in the bone marrow.

14 Dec 2012

Boehringer Ingelheim to commence volasertib plus LDAC Phase III study for AML

New positive Phase II results from an interim analysis of the randomised Phase I/II study involving the company's investigational haematology/oncology compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy were presented at the 54th American Society of Hematology (ASH) annual meeting in Atlanta, USA.

10 Dec 2012

Hemostatic testing may explain heavy menstrual bleeding

Results of a US study show that hemostatic screening tests are important in the evaluation of young women with heavy menstrual bleeding.

24 Oct 2012

Wheeze predicts sickle cell disease crisis

Wheezing is a significant indicator for morbidity in patients with sickle cell disease, US researchers believe.

26 Sep 2012